secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioCardia, Inc. (BCDA)
CIK:        0000925741
Form:       8-K
Filed at:   2026-06-05T12:00:10+00:00
Accession:  0001437749-26-019653
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCardia: FDA confirms CardiAMP HF II trial may support PMA for HFrEF therapy
------------------------------------------------------------------------------

- FDA CBER Q-Sub meeting minutes confirm ongoing CardiAMP HF II trial may support Premarket Approval (PMA) for market clearance.
- PMA is the most rigorous FDA device marketing application; previously FDA typically required two trials for large indications like HFrEF.
- FDA had previously determined CardiAMP Cell Therapy System safe, enabling CMS reimbursement in trial.
- Over 1 million U.S. ischemic HFrEF patients could potentially benefit from CardiAMP Cell Therapy.
- Company plans to complete U.S. trial for PMA and submit for regulatory approval in Japan with a post-marketing study.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/925741/000143774926019653/0001437749-26-019653-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/925741/000143774926019653/bcda20260605d_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-019653

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer